ClinicalTrials.gg
RecruitingNCT07086768Updated Oct 15, 2026

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of BSI-082 and Trastuzumab deruxtecan in Solid Tumor, Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Lei Zheng. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Lei Zheng · Phase 1, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 15, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
776th of 1,866
57 · median 43
Started
2026
with 85 others
Phase 1
710 of 2,057
127 open now
Primary completion
2027-08
later than 270 of 542 live
Registered
1,960th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 776th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 86 that started in 2026, is one of 710 in phase 1, reaches primary completion later than 270 of the 542 other live ones, and was the 1,960th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This is a study that will enroll patients with cancer who have tumors that may have spread. The patients will know what medication they are being given.

There will be 2 parts to the study. For the first part of the study only one medication will be taken, and the dose changed to a higher dose over time.

In the second part of the study tow medications will be taken and the dose of the medication may be changed to a higher dose.

Read the detailed description

Phase 1a monotherapy dose-escalation part will establish the safety and tolerability of BSI-082 as single agent. Up to 30 patients with locally advanced or metastatic solid tumors who have relapsed, or been non-responsive, or have developed disease progression through standard systemic therapy, or have been ineligible for standard systemic therapy known to confer clinical benefit will be enrolled. Recommended dose for expansion (RDE) will be determined in this phase and used in the phase 1b study.

Phase 1b combination dose-escalation and dose-expansion part will enroll up to 27 patients with Her2 positive locally advanced solid tumors that are indicated for the Standard of care T-DXd treatment.

03

Conditions studied

  • Solid Tumor
  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • anti-SIRPα antibody
  • anti-signal regulatory protein alpha
  • Dose Escalation
  • Dose Expansion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Read, understood, and provided written and must be willing to comply with all study requirements and procedures.
  2. Adults ≥ 18 years of age at the time of informed consent form is signed.
  3. Patients with or cytologically confirmed locally advanced or solid tumors who have , or been non-responsive, or have developed disease progression through standard systemic therapy, or have been ineligible for standard systemic therapy known to confer clinical benefit.
  4. Patients having an FDA-approved indication for T-DXd (only for Phase 1b dose expansion).
  5. With 4 weeks or 5 half-lives (whichever is shorter) of prior anticancer therapies (only for Phase 1a dose escalation).
  6. ≥ 12 weeks.
  7. (ECOG) Performance Status (PS) of 0 or 1.
  8. Presence of at least 1 based on computed tomography (CT) or magnetic resonance imaging (MRI) per RECISIT V1.1.
  9. Has a (LVEF) ≥50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrollment.
  10. Main organ functions meet the following criteria:

    • (ANC) ≥ 1.5×109/L
    • counts ≥ 100×109/L
    • ≥ 9 g/dL (without recent red blood cell transfusion within 2 weeks prior to study entry)
    • ≥ 40 mL/min per the Cockcroft and Gault formula.
    • ≤ 2.5×Upper Limit Normal ( or patients with hepatic metastasis ≤ 5×ULN
    • ALT ≤ 2.5×ULN or patients with hepatic metastasis ≤ 5×ULN
    • Total ≤ 1.5×ULN, except for patients with Gilbert's syndrome from whom total bilirubin \< 3.0 × ULN or direct bilirubin \< 1.5 × ULN
  11. Both male and female of patients enrolled in this trial as well as their partners must agree to use highly effective during the study and for at least 10 months after discontinuing study treatment. Patients and/or partners who are surgically sterile or are exempt from this requirement.

Exclusion criteria

Exclusion Criteria:

  1. Known allergies, , or intolerance to monoclonal antibodies (mAbs) or formulation components of BSI-082.
  2. Prior therapy with any SIRPα or 7 targeting agents.
  3. Has active disease or a documented history of autoimmune disease, or history of potential autoimmune syndrome that required systemic or medications, except for patients with vitiligo, endocrinopathies, type 1 diabetes, or patients with resolved childhood asthma/atopy or other syndromes which would not be expected to recur in the absence of an external trigger (e.g., drug-related serum sickness or post-streptococcal glomerulonephritis). Patients with mild asthma who require intermittent use of bronchodilators (such as albuterol) and those who have not been hospitalized for asthma in the preceding 3 years will not be excluded from this study.
  4. Toxicities of prior anticancer therapies have not resolved to ≤ Grade 1 or to baseline) prior to the first dose of study treatment (excluding alopecia, vitiligo, endocrinopathies on stable hormone replacement therapy, Grade 2 neuropathy from taxanes or platinum containing therapies and Grade 2 hearing loss from platinum-containing therapies).
  5. Has other , except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 5 years.
  6. Occurrence of immune related toxicity necessitating permanent discontinuation or immune related toxicity that required treatment with a TNF inhibitor (e.g., infliximab) in patients with previous immunotherapy.
  7. Medical history of myocardial (MI) within 6 months before study enrollment, symptomatic congestive heart failure (CHF) ( [NYHA] Class II to IV).
  8. Any of the following within 6 months of enrollment: cerebrovascular accident, , other arterial thromboembolic events, or pulmonary embolism.
  9. Has a corrected with Fridericia's formula (QTcF) prolongation to >470 ms based on average of the screening triplicate 12-lead (ECG).
  10. Uncontrolled hypertension (resting systolic blood pressure>180 mmHg or diastolic blood pressure>110 mmHg) and/or severe arrhythmia within 28 days before enrollment.
  11. Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
  12. Has lung-specific intercurrent illnesses including, but not limited to, any underlying pulmonary disorder.
  13. Any autoimmune, connective tissue or inflammatory disorders where there is documented or suspicion of pulmonary involvement at the time of screening.
  14. Prior complete pneumonectomy.
  15. Has spinal cord compression or clinically active central nervous system , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
  16. Has uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  17. Has active primary immunodeficiency or active (HIV) infection as determined by plasma HIV ribonucleic acid (RNA) viral load and CD4 count. For the Dose-expansion phase only, participants with undetectable viral load or normalized CD4 count (CD4+ T-cell counts ≥ 350 cells/μL) and no opportunistic infection within the past 12 months will be eligible. These participants must be on established antiretroviral therapy for at least 4 weeks and have an HIV viral load \<400 copies/mL prior to enrollment.
  18. Has active or C infection. Participants with past virus (HCV) infection and positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. Participants with past or resolved hepatitis B virus infection are eligible only if confirmed by the Investigator.
  19. Has received a live, attenuated vaccine (messenger ribonucleic acid [mRNA] and replication-deficient adenoviral vaccines are not considered live, attenuated vaccines) within 30 days prior to first exposure to study drug(s).
  20. Has any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or trial drug administration or could interfere with the interpretation of trial results would make the patient inappropriate for entry into the trial.
  21. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may interfere with the participant's participation in the clinical study or evaluation of the clinical study results.
  22. Women who are pregnant or lactating. All female patients of must have a negative serum pregnancy test prior to the first dose of study treatment.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Cohort 1: monotherapy

    BSI-082 0.3mg/kg will be administrated as an IV infusion on Day 1 of each 21-day treatment cycle

    Drug: BSI-082

  • Experimental
    Cohort 2: monotherapy

    BSI-082 1mg/kg will be administrated as an IV infusion on Day 1 of each 21-day treatment cycle

    Drug: BSI-082

  • Experimental
    Cohort 3: monotherapy

    BSI-082 3mg/kg will be administrated as an IV infusion on Day 1 of each 21-day treatment cycle

    Drug: BSI-082

  • Experimental
    Cohort 4: monotherapy

    BSI-082 10mg/kg will be administrated as an IV infusion on Day 1 of each 21-day treatment cycle

    Drug: BSI-082

  • Experimental
    Cohort 5: monotherapy

    BSI-082 20mg/kg will be administrated as an IV infusion on Day 1 of each 21-day treatment cycle

    Drug: BSI-082

  • Experimental
    Cohort b1: combined therapy

    Lower dose cohort of BSI-082 with established dose of T-DXd

    Drug: BSI-082 · Other: Trastuzumab deruxtecan

  • Experimental
    Cohort b2: combined therapy

    Higher dose cohort of BSI-082 with established dose of T-DXd

    Drug: BSI-082 · Other: Trastuzumab deruxtecan

Interventions

  • DrugBSI-082

    BSI-082 is a sterile solution for injection which contains the active ingredient at the nominal concentration of 50.0 mg/mL. T

  • OtherTrastuzumab deruxtecan

    T-DXd: Administrate as per the drug package insert and Investigator's guidance, and T-DXd can be continued after the patients been taken off from the study.

    Also known as: Standard of care treatment with

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Dose limiting toxicity Events

    Adverse events (AEs) as characterized by type, frequency, severity (as graded by national cancer institute common terminology criteria for adverse events, NCI CTCAE V5.0), timing, seriousness, and relationship to study treatment. •And Vital sign abnormalities and laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE V5.0) and timing.

    Time frame: Baseline to 42 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Any manuscript, abstract or other publication or presentation of results or information arising in connection with the trial (including any ancillary trial involving trial subjects) must be prepared in conjunction with the Mays Cancer Center Data Safety Monitoring Board, the trial's statistician, and verification that all study data to be used for the publication has been monitored for accuracy by the Mays Quality Assurance (QA) team prior to publication or presentation.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After study completion and data analysis for publication.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.

Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 18 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Jul 25, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Aug 7, 2027
CompletionEst.
Aug 7, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Collaborators added: Biosion, Inc.; collaborators removed: Biosin USA, Inc.
Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    Sponsor Collaborators added: Biosion, Inc.; collaborators removed: Biosin USA, Inc.
  2. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07086768
Lead sponsor
Lei Zheng
Collaborators
Biosion, Inc.
Responsible party
Lei Zheng (Executive Director of University of Texas Health Science Center at San Antonio Cancer Center, The University of Texas Health Science Center at San Antonio) — Sponsor-investigator
First posted
Jul 25, 2025
Start date
Jan 26, 2026
Primary completion
Aug 7, 2027 (estimated)
Completion
Aug 7, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

John Sarantopoulos, MD
Contact
sarantopoulo@uthscsa.edu
210 450 5946
Epp Goodwin
Contact
GOODWINE@uthscsa.edu
210 450 5798
Lei Zheng, MD
study director · The University of Texas Health Science Center at San Antonio
John Sarantopoulos, MD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion